Vaccine

General information

Currently there are about 165 different vaccines for COVID-19 being developed around the world. The main types of vaccines include vector, inactivated, nucleic acid-based (DNA and mRNA) and recombinant protein-based vaccines. Russian adenovirus vector-based vaccine was registered by the Russian Ministry of Health on August 11 and became the first registered COVID-19 vaccine on the market. The announcement created a so-called “Sputnik moment” for the global community.

In 1957 the successful launch of the first space satellite by the Soviet Union reinvigorated space research around the world. The new Russian COVID-19 vaccine is therefore called Sputnik V.

This website has been created to provide accurate and up-to-date information about Sputnik V and to combat the misinformation campaign launched against it in the international media.

Russian Health Ministry registration certificate

Sputnik V vaccine
Sputnik V vaccine

How adenoviral vector-based vaccines work

“Vectors” are vehicles, which can induce a genetic material from another virus into a cell. The gene from adenovirus, which causes the infection, is removed while a gene with the code of a protein from another virus spike is inserted. This inserted element is safe for the body but still helps the immune system to react and produce antibodies, which protect us from the infection.

The technological platform of adenovirus-based vectors makes it easier and faster to create new vaccines through modifying the initial carrier vector with genetic material from new emerging viruses that helps to create new vaccines in relatively short time. Such vaccines provoke a strong response from a human immune system.

Human adenoviruses are considered as some of the easiest to engineer in this way and therefore they have become very popular as vectors.

Learn more about how adenovirus-based vector vaccines work

Learn more about the successful experience of the Gamaleya Center on the development of vaccines against Ebola based on an adenovirus vector

Sputnik V vaccine Sputnik V vaccine

Safety and efficacy

After the start of the COVID-19 pandemic Russian researchers extracted a fragment of genetic material from novel coronavirus SARS-COV-2, which codes information about the structure of the spike S-protein, which forms the virus’ “crown” and is responsible for connection with human cells. They inserted it into a familiar adenovirus vector for delivery into a human cell creating the world’s first COVID-19 vaccine.

In order to ensure lasting immunity Russian scientists came up with a breakthrough idea to use two different types of adenovirus vectors (rAd26 and rAd5) for the first and second vaccination, boosting the effect of the vaccine.

The use of human adenoviruses as vectors is safe because these viruses, which cause the common cold, are not novel and have been around for thousands of years.

ATTITUDE TOWARDS THE SPUTNIK V VACCINE IN RUSSIA

LEVEL OF AWARENESS AMONG RUSSIAN CITIZENS ON DEVELOPING AND REGISTERING THE RUSSIAN-PRODUCED VACCINE
90%
The population as a whole
97%
Medical industry workers
ATTITUDE TOWARDS THE QUALITY OF RUSSIAN-PRODUCED VACCINES
Mostly
good
43%
Mostly
bad
14%
43% of the population believes that the vaccine is a high-quality one
Mostly
good
53%
Mostly
bad
5%
53% of the population in the older age category believe that the vaccine is a high-quality one
Mostly
good
61%
61% of medical industry workers who are older believe that the vaccine is a high-quality one
CONFIDENCE IN THE EFFICACY OF THE RUSSIAN-PRODUCED VACCINE AGAINST THE EPIDEMIC
53%
53% believe that the Russian-produced vaccine will be able to stop the epidemic
LEVEL OF CONFIDENCE IN THE RUSSIAN-PRODUCED VACCINE IN COMPARISION WITH VACCINES PRODUCED IN OTHER COUNTRIES
62%
The vast majority give preference to the Russian-produced vaccine
80%
80% of those who are elderly give preference to the Russian-produced vaccine
12%
Only 12% lend support to foreign vaccines


Key results of a survey taken by FOM (Public Opinion Foundation) (Russia)

ATTITUDE TOWARDS THE SPUTNIK V VACCINE IN THE WORLD

LEVEL OF CONFIDENCE IN MEXICO IN THE VACCINE, DEPENDING ON ITS COUNTRY OF ORIGIN
High
Medium
Low
Very Low
No response
RUSSIA
32
34
17
12
5
UNITED STATES
31
29
17
19
4
GREAT BRITAIN
30
33
18
12
7
FRANCE
28
37
16
13
6
MEXICO
22
41
26
8
3
CHINA
20
24
22
31
3

EL FINANCIERO (Mexico)
LEVEL OF CONFIDENCE IN THE RUSSIAN-PRODUCED VACCINE IN THE PHILIPPINES
50%
Would agree to have the vaccination administered after the drug is approved and becomes available



WR Numero Research (the Philippines)

Message has been successfully sent!